Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration

NCT02611778 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

712

Enrollment

INDUSTRY

Sponsor class

Conditions

Age-related Macular Degeneration (AMD)

Interventions

BIOLOGICAL: ranibizumab

Sponsor

Bioeq GmbH